January 03, 2020
The latest solutions to more affordable treatment for people with diabetes come as three new Novo Nordisk initiatives: the My$99Insulin program, follow-on brands of insulins, and an immediate supply option for those in need.
These new options are in addition to Novo Nordisk’s existing patient assistance programs, copay cards, and $25/vial human insulin, the company announced Thursday.
For people struggling or in immediate need of insulin, the Immediate Supply option will allow patients to call 1.844.NOVO4ME or use NovoCare.com to see if they are eligible for a free, one time, immediate supply of up to three vials or two packs of insulin pens with a valid prescription.
The My$99Insulin program will enable patients without insurance to get up to three vials or two packs of FlexPen/FlexTouch/Penfill pens of any combination of Novo Nordisk Inc insulin products. Patients need only enroll on their website and download a card or have it sent to them via email or phone to be redeemed at their pharmacy.
Novo Nordisk is now also stocking authorized generics or follow-on brands of its insulin product Novolog, that will be made available to order at the pharmacy and pick up in 1 to 3 business days. According to Novo Nordisk’s press release, follow-on brand product pricing is as follows:
- Insulin Aspart (FOB) vial: $144.68
- Insulin Aspart PenFill® cartridge (FOB) - 5x3mL: $268.73
- Insulin Aspart FlexPen® (FOB) - 5x3mL: $279.41
- Insulin Aspart Mix 70/30 (FOB) 10mL vial: $150.06
- Insulin Aspart Mix 70/30 FlexPen® (FOB) - 5x3mL: $279.41
“We know some people still struggle to afford their insulin and we want to help. We’ve talked to people, including those who have been critical of us, and it’s clear there is no one solution that will work for everyone and people need options,” said Doug Langa, executive vice president, North America Operations and president of Novo Nordisk Inc.
Novo Nordisk. Novo Nordisk’s new insulin affordability offerings now available in the US [press release]. https://www.novonordisk-us.com/media/news-releases.html?122978. Published January 2, 2020. Accessed January 3, 2020.